EAEriko Aotani

Eriko Aotani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eriko Aotani has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG symptom benefit study (SBS).

    by Felicia Roncolato, Rachel O'Connell, Luke Buizen, Florence Joly, Anne Lanceley, Felix Hilpert, Aikou Okamoto, Eriko Aotani, Sandro Pignata, Paul P. Donnellan, et al.

    5508Background: 110 (19%) of the 570 women with PRROC enrolled in SBS stopped chemotherapy within 8 weeks. We sought to identify baseline characteristics, including QOL and clinical factors, that were associated with overall survival and stopping chemotherapy early. Methods: QOL domains were measured with the EORTC QLQ-C30 and QLQ-OV28. QLQ-C30 subscales were dichotomised using cut-points recommended by Diouf et al (The Oncologist 2015). Cox’s Proportional Hazards regression was used to assess univariable and multivariable associations with overall survival. Clinical factors for the multivariable model were selected using backward elimination; candidate variables included those with P<0.05 in univariable analyses. The association between baseline QOL domains and stopping chemotherapy early was determined by categorising the QOL domains and using a chi-squared test. Results: Univariable analyses of baseline QOL data (N=545) showed that physical function (PF), role function (RF), global health status (GHS) ...


  • Identification of adverse events that have a negative impact on quality of life in a clinical trial comparing docetaxel versus S-1 with cisplatin in lung cancer

    by Eriko Aotani, Tetsutaro Hamano, Akihiko Gemma, Masahiro Takeuchi, Toru Takebayashi, Kunihiko Kobayashi

    In the CATS (Cisplatin And TS-1) randomized trial comparing cisplatin plus either docetaxel (DP arm) or TS-1 (SP arm) in lung cancer, efficacy was found to be equivalent but the global quality of life (QOL) score was higher in the SP arm. The purpose of the current study was to identify which of the adverse events (AEs) contributed to the deterioration of QOL. QOL and AE data from the CATS trial were used to quantitatively analyze the relationship between deterioration of QOL score and occurrence of AEs. Subtracted values of the QOL score from post-chemotherapy to pre-chemotherapy were fully compared between patients with or without each AE (Student’s t test, significance level = 0.001). Multivariate linear regression analysis was also performed. Analysis of variance was performed to identify whether grade of AE(s) might be significantly correlated with the deterioration of the QOL score (significance level of 0.05). As expected, gastrointestinal (GI) toxicities were associated with worsening of a variety of QOL items in both trial arms, detected by both univariate and multivariate analysis (p < 0.001 and p < 0.0001, respectively). Multivariate analysis unpredictably indicated that an increase in serum bilirubin level was the only AE that was uniquely associated with worsening of physical functioning (p = 0.0002), cognitive functioning (p < 0.0001), and financial problems (p = 0.0005) in the DP arm, although not in the SP arm. GI toxicities tended to be prolonged in the SP arm. An increase in serum bilirubin level may contribute to the worse global QOL of subjects in the DP arm in the CATS trial. The method we used here may be a unique approach to identify unpredictable AE(s) that worsen the QOL of patients treated by chemotherapy.


    • 1 June 2012
      • p. 59-66

    [Current movement in global clinical trials--discussion at Gynecologic Cancer Intergroup (GCIG)].

    by Satoru Sagae, Daisuke Aoki, Nobuyuki Susumu, Aikou Okamoto, Eriko Aotani, Masahiro Takeuchi, Masanori Mandai